SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001549595-24-000098
Filing Date
2024-07-11
Accepted
2024-07-11 16:07:20
Documents
66
Period of Report
2024-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-20240531.htm   iXBRL 10-Q 1481598
2 EX-31.1 nrix-20240531x10qxex311.htm EX-31.1 10852
3 EX-31.2 nrix-20240531x10qxex312.htm EX-31.2 10842
4 EX-32.1 nrix-20240531x10qxex321.htm EX-32.1 8422
  Complete submission text file 0001549595-24-000098.txt   6274228

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20240531.xsd EX-101.SCH 42640
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20240531_cal.xml EX-101.CAL 52942
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20240531_def.xml EX-101.DEF 204230
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20240531_lab.xml EX-101.LAB 576803
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20240531_pre.xml EX-101.PRE 388417
68 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20240531_htm.xml XML 648870
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 241112126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)